Guanfacine Tablet, Extended Release
Product Images NDC 72162-1799

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Guanfacine (NDC 72162-1799). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Image 05)

A line graph comparing guanfacine plasma concentration (ng/mL) over 24 hours between guanfacine extended-release tablets 1 mg once daily and Tenex 1 mg once daily. The x-axis represents time in hours, and the y-axis shows plasma concentration levels.*

FDA Label Image

Figure 2 (Image 06)

A forest plot chart illustrating fold changes and 90% confidence intervals in pharmacokinetic parameters Cmax and AUC due to various CYP3A4/5 inhibitors, inducers, and other substances. The x-axis shows the fold change relative to reference from 0 to 5. Data points for Ketoconazole, Fluconazole, Rifampin, Efavirenz, Oral Methylphenidate, and Lisdexamfetamine Dimesylate are presented with corresponding fold change values and confidence intervals for Cmax and AUC.*

FDA Label Image

Figure 3 (Image 07)

A chart displaying the fold change and 90% confidence intervals for pharmacokinetic parameters Cmax and AUC of two interacting drugs, Oral Methylphenidate and Lisdexamfetamine Dimesylate. The fold change relative to reference is shown on the x-axis from 0.0 to 2.0, with markers indicating changes near 1.0 for both drugs and parameters.*

FDA Label Image

Label (Lbl721621799)

Label for Guanfacine Extended-Release Tablets, USP, 2 mg strength. The label indicates 100 tablets per package, labeled by Bryant Ranch Prepack and manufactured by Ohm Laboratories Inc. Storage instructions specify 20° to 25°C, with warnings to keep out of reach of children and avoid crushing or chewing tablets before swallowing. Includes NDC 72162-1799-1 and barcodes.*

FDA Label Image

Spl-guanfacine-figure 4 (Spl Guanfacine Figure 4)

A line graph showing treatment failure over time in days. The x-axis represents time to treatment failure (days), ranging from 0 to about 200, and the y-axis represents treatment failure percentage from 0 to 100%. Two lines are displayed: a solid line for Placebo and a dashed line for SPD503, indicating different rates of treatment failure over time.*

FDA Label Image

Structure (Structure)

Chemical structure diagram of Guanfacine hydrochloride showing its molecular configuration with chlorine atoms, amine groups, and other chemical bonds.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.